Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Achieve Life Sciences
People's Hospital of Xinjiang Uygur Autonomous Region
Institut Claudius Regaud
National Institutes of Health Clinical Center (CC)
Vastra Gotaland Region
AstraZeneca
Bristol-Myers Squibb
Ohio State University Comprehensive Cancer Center
Travera Inc
The Methodist Hospital Research Institute
Montefiore Medical Center
Sandoz
IO Biotech
Novartis
Amgen
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca
M.D. Anderson Cancer Center
Affiliated Hospital of Nantong University
Brown University
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Roswell Park Cancer Institute
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Pfizer
Daiichi Sankyo
Shanxi Province Cancer Hospital